布利纳图莫马布用于成人MRD阴性急性淋巴细胞白血病
Mark R Litzow1, Zhuoxin Sun1, Ryan J Mattison1
1From the Mayo Clinic, Rochester, MN (M.R.L., C.L.W., M.A.E.); Dana-Farber Cancer Institute, Boston (Z.S., D.J.D., R.M.S.); the University of Wisconsin Carbone Cancer Center, Madison (R.J.M.), and the Medical College of Wisconsin, Milwaukee (E.L.A.); Montefiore Medical Center Moses Campus (E.M.P., J.R.) and Memorial Sloan Kettering Cancer Center (Y. Zhang, M.S.T.) - both in New York; the Department of Pathology and the Center for Excellence for Leukemia Studies (K.G.R., Y. Zhao, C.G.M.) and the Center for Applied Bioinformatics (G.W., T.-C.C., W.Z.), St. Jude's Children's Research Hospital, Memphis, TN; Case Western Reserve University (H.M.L.) and Cleveland Clinic Foundation (A.S.A.), Cleveland, and the Ohio State University Comprehensive Cancer Center, Columbus (B.B.) - all in Ohio; Shaare Zedek Medical Center, Jerusalem, Israel (J.M.R.); Stanford Cancer Institute, Palo Alto (D.A.A., M.L.), the University of California, San Diego, Moores Cancer Center, La Jolla (M.J.W., D.T.), and the University of California, Irvine, Health Cancer Center-Newport, Orange (D.J.) - all in California; the University of Chicago (D.A.A.) and Northwestern University (S.N.D.) - both in Chicago; Hopital Maisonneuve-Rosemont, Montreal (J.B.); the University of Washington, Seattle (B.L.W.); Johns Hopkins University Sidney Kimmel Cancer Center, Baltimore (K.W.P.), and the National Cancer Institute, National Institutes of Health, Bethesda (E.S., R.F.L.) - both in Maryland; the University of Pennsylvania Abramson Cancer Center, Philadelphia (N.F., S.M.L.); Yale School of Medicine, New Haven, CT (S.D.G.); the Washington University in St. Louis School of Medicine, St. Louis (G.L.U.); the University of Kansas Cancer Center, Westwood (T.L.L.); Virginia Commonwealth University Massey Cancer Center, Richmond (S.B.P.); the University of Alabama at Birmingham, Birmingham (P.V.); and Wake Forest University Health Sciences, Winston-Salem (R.R.B.), and Duke University Medical Center, Durham (H.P.E.) - both in North Carolina.
为化疗添加布利纳图莫马布显著改善了B细胞前体急性淋巴细胞白血病 (BCP-ALL) 缓解的成年人的整体存活率. 这种治疗为这些患者提供了更好的长期生存机会.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
背景情况:
- 患有B细胞前体急性淋巴细胞白血病 (BCP-ALL) 的老年人即使在通过化疗实现可测量的残留疾病 (MRD) 阴性缓解后,也经常复发.
- 作为双特异性T细胞参与剂的布利纳图莫马布已被批准用于复发性/耐药性BCP-ALL,并且可能有利于MRD阴性缓解的患者.
研究的目的:
- 为了评估添加blinatumomab在MRD阴性BCP-ALL.ALL的成年患者的整合化疗中的疗效.
- 为了比较blinatumomab加化疗和单独化疗之间的整体存活率 (OS) 和无复发存活率 (RFS).
主要方法:
- 一项3期试验随机选择了30至70岁的BCR::ABL1阴性BCP-ALL在MRD阴性缓解 (少于0.01%的白血病细胞) 的患者,接受布利纳马布加固化疗或单独的固化化疗.
- 主要终点是整体存活率;无复发存活率是次要终点.
主要成果:
- 随访时间中位数为43个月,布利纳图马布组的整体存活率显著改善 (3年存活率:85%与68%相比;HR 0.41,P=0.002).
- 在布利纳图马布组,无复发的3年生存率更高 (80%对64%;HR0.53).
- 神经精神事件在blinatumomab手臂中更频繁.
结论:
- 将布利纳图马布添加到巩固化疗中,显著改善了MRD阴性BCP-ALL.ALL成人患者的整体存活率.
- 布利纳图马布代表了一种有价值的治疗选择,用于维持BCP-ALL的缓解.
更多相关视频
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
